AQST News and Press, Aquestive Therapeutics Inc. From 06/06/22

Aquestive Therapeutics (NASDAQ:AQST) +1.5% announced Monday a direct stock offering worth $8.5M, comprising of 8.85M shares priced at $0.96 each. It will also include the warrants to purchase up to an aggregate of 8.85M shares for 5-year term, exercisable at a purchase price of...

WARREN, N.J., June 06, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients’ problems with current standards of care and provide transformative products to improve their lives, today announced that it has...

Over the past couple of years, my Aquestive Therapeutics (AQST) thesis has been fixated on valuation and their two most important value drivers, Libervant and AQST-109. AQST-109 is the first and only oral epinephrine candidate to establish grades comparable to epinephrine auto-injecto...

Aquestive Therapeutics (NASDAQ:AQST) said Tuesday Keith Kendall, president, CEO and member of the board, will resign. AQST appointed Daniel Barber, current COO, to succeed Kendall as president, CEO and member of the board, effective immediately. Kendall will assist in the transition of the CE...

Daniel Barber, current Chief Operating Officer of Aquestive, appointed as President and Chief Executive Officer and member of Board of Directors Keith Kendall, President and Chief Executive Officer and member of Board of Directors, will be leaving the Company Keith Kendall engaged...

WARREN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management...

Image source: The Motley Fool. Aquestive Therapeutics, Inc. (NASDAQ: AQST) Q1 2022 Earnings Call May 04, 2022 , 8:00 a.m. ET Operator Continue reading For further details see: Aquestive Therapeutics, Inc. (AQST) Q1 2022 Earnings Call Tran...

Aquestive Therapeutics, Inc. (AQST) Q1 2022 Results Conference Call May 04, 2022 08:00 AM ET Company Participants Bennett Watson - Investor Relations Keith Kendall - Chief Executive Officer Ernie Toth - Chief Financial Officer Daniel Barber - Chief Operating Officer Conference Call Participan...

Aquestive Therapeutics press release (NASDAQ:AQST): Q1 GAAP EPS of -$0.32 beats by $0.09. Revenue of $12.27M (+10.3% Y/Y) beats by $2.15M. Cash and cash equivalents of $14.7M as of March 31, 2022 vs $28M as of Dec. 31, 2021. Reconfirming FY 2022 financial outlook. Company expects total r...

FDA continues to consider orphan drug exclusivity issues regarding Libervant's NDA Common stock purchase agreement secured for up to $40 million Part 3 of EPIPHAST trial for AQST-109 commenced in April and on track to report topline data in second quarter 2022 Hosts investment...